DE69408668D1 - Benz(b)azepin-2,5-dione verwendbar in der behandlung neurodegenerativer störungen - Google Patents

Benz(b)azepin-2,5-dione verwendbar in der behandlung neurodegenerativer störungen

Info

Publication number
DE69408668D1
DE69408668D1 DE69408668T DE69408668T DE69408668D1 DE 69408668 D1 DE69408668 D1 DE 69408668D1 DE 69408668 T DE69408668 T DE 69408668T DE 69408668 T DE69408668 T DE 69408668T DE 69408668 D1 DE69408668 D1 DE 69408668D1
Authority
DE
Germany
Prior art keywords
benz
treatment
neurodegenerative disorders
azepine
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69408668T
Other languages
English (en)
Other versions
DE69408668T2 (de
Inventor
Marc Chapdelaine
Timothy Davenport
Laura Garcia-Davenport
Paul Jackson
Jeffrey Mckinney
Charles Mclaren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of DE69408668D1 publication Critical patent/DE69408668D1/de
Application granted granted Critical
Publication of DE69408668T2 publication Critical patent/DE69408668T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
DE69408668T 1993-06-10 1994-06-09 Benz(b)azepin-2,5-dione verwendbar in der behandlung neurodegenerativer störungen Expired - Fee Related DE69408668T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939311948A GB9311948D0 (en) 1993-06-10 1993-06-10 Substituted nitrogen heterocycles
PCT/GB1994/001243 WO1994029275A1 (en) 1993-06-10 1994-06-09 Benz(b)azepine-2,5-diones useful in the treatment of neurodegenerative disorders

Publications (2)

Publication Number Publication Date
DE69408668D1 true DE69408668D1 (de) 1998-04-02
DE69408668T2 DE69408668T2 (de) 1998-07-09

Family

ID=10736919

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69408668T Expired - Fee Related DE69408668T2 (de) 1993-06-10 1994-06-09 Benz(b)azepin-2,5-dione verwendbar in der behandlung neurodegenerativer störungen

Country Status (15)

Country Link
US (2) US5502048A (de)
EP (1) EP0702673B1 (de)
JP (1) JPH08511513A (de)
AT (1) ATE163409T1 (de)
AU (1) AU684789B2 (de)
CA (1) CA2161251A1 (de)
DE (1) DE69408668T2 (de)
DK (1) DK0702673T3 (de)
ES (1) ES2112546T3 (de)
GB (2) GB9311948D0 (de)
HU (1) HU9501709D0 (de)
IL (1) IL109968A (de)
NZ (1) NZ266855A (de)
TW (1) TW282459B (de)
WO (1) WO1994029275A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9212308D0 (en) * 1992-06-10 1992-07-22 Ici Plc Therapeutic compositions
GB9311948D0 (en) * 1993-06-10 1993-07-28 Zeneca Ltd Substituted nitrogen heterocycles
US5801168A (en) * 1994-06-09 1998-09-01 Zeneca Limited Substituted nitrogen heterocycles
US5977125A (en) 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
US5476933A (en) * 1994-11-16 1995-12-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Azepine synthesis via a diels-alder reaction
EP0888350A1 (de) * 1996-03-08 1999-01-07 Zeneca Limited Azolobenzazepinderivate als neurologisch aktive mittel
US6191166B1 (en) 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6211235B1 (en) 1996-11-22 2001-04-03 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6683075B1 (en) 1996-12-23 2004-01-27 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) * 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) * 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US20050192265A1 (en) * 2003-03-20 2005-09-01 Thompson Richard C. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
GB0900641D0 (en) * 2009-01-15 2009-02-25 Syngenta Ltd Novel herbicides
GB0901835D0 (en) * 2009-02-04 2009-03-11 Syngenta Ltd Novel herbicides

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1340334A (en) * 1970-07-06 1973-12-12 Rees A H Synthesis of benzazetropolones and hence of kynurenic acids
JPS5129522B2 (de) * 1972-07-13 1976-08-26
JPS5520970B2 (de) * 1972-07-15 1980-06-06
GB2103614B (en) * 1981-08-11 1984-11-21 Ciba Geigy Ag Benzazepin-2-ones
US4410520A (en) * 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
US4473575A (en) * 1982-07-19 1984-09-25 Ciba-Geigy Corporation 3-Amino-(1)-benzazepin-2-one-1-alkanoic acids
US4575503A (en) * 1983-02-10 1986-03-11 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
US4477446A (en) * 1983-07-01 1984-10-16 Usv Pharmaceutical Corporation 1-Benzazepines and their pharmaceutical uses
DE3416695A1 (de) * 1984-05-05 1985-11-07 Bayer Ag, 5090 Leverkusen Amidinohydrazone von tetralin-, chromon-, thiochromon- und tretrahydrochinolin-derivaten, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US5322943A (en) * 1985-09-12 1994-06-21 The Upjohn Company Piperazine compounds which are substituted
US5266684A (en) * 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US4885364A (en) * 1988-11-23 1989-12-05 E. R. Squibb & Sons, Inc. Resolution process for benzazepine intermediates
JPH0347123A (ja) * 1989-05-05 1991-02-28 G D Searle & Co インドール―２―カルボキシレート化合物類を含有するｃｎｓ疾患治療用組成物
US5229413A (en) * 1989-05-05 1993-07-20 G. D. Searle & Co. Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders
US5026700A (en) * 1989-05-16 1991-06-25 Merrell Dow Pharmaceuticals Certain quinolines and thienopyridines as excitatory amino acid antagonists
CA2016465A1 (en) * 1989-06-02 1990-12-02 Zola Phillip Horovitz Method for preventing or treating anxiety employing a calcium channel blocker
JPH0334977A (ja) * 1989-06-29 1991-02-14 Yoshitomi Pharmaceut Ind Ltd イミダゾリルベンゾラクタム化合物
KR0167349B1 (ko) * 1989-10-20 1999-02-18 오스카 아끼히꼬 벤조헤테로 고리 화합물
US5622832A (en) * 1990-02-28 1997-04-22 Genetics Institute, Inc. Arachidonic acid releasing phospholipase A2 enzyme and methods of use
US5051442A (en) * 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
US5182366A (en) * 1990-05-15 1993-01-26 Huebner Verena D Controlled synthesis of peptide mixtures using mixed resins
DE69113115T2 (de) * 1990-05-31 1996-06-13 Merck Sharp & Dohme Dioxo-tetrahydrochinolinderivate.
GB9022785D0 (en) * 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
AU641052B2 (en) * 1990-11-02 1993-09-09 Aventisub Ii Inc. 3-amidoindolyl derivatives
US5189054A (en) * 1990-11-02 1993-02-23 Merrell Dow Pharmaceuticals Inc. 3-amidoindolyl derivatives and pharmaceutical compositions thereof
GB9026389D0 (en) * 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
GB9100028D0 (en) * 1991-01-02 1991-02-20 Ici Plc Compounds
WO1992013535A1 (en) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
EP0542689B1 (de) * 1991-11-15 1998-09-23 Phafag Aktiengesellschaft Verwendung von 1-(aminoalkyl)-3-Quinoxalin-2-on Derivaten zur Herstellung von neuroprotektiven Mitteln
JP2712144B2 (ja) * 1992-02-06 1998-02-10 田辺製薬株式会社 血小板凝集抑制組成物
GB9206266D0 (en) * 1992-03-23 1992-05-06 Merck Sharp & Dohme Therapeutic agents
GB9212308D0 (en) * 1992-06-10 1992-07-22 Ici Plc Therapeutic compositions
DK0647137T3 (da) * 1992-06-22 2008-12-08 State Of Oregon Through Oregon Glycinreceptorantagonister og anvendelse deraf
CA2098446A1 (en) * 1992-09-30 1994-03-31 Eckard Weber 2,5-dihydro-2,5-dioxo-1h-azepines and 2,5-dihydro-2-oxo-1h-azepines and the use thereof as excitatory amino acid and glycine receptor antagonists
US5514690A (en) * 1992-11-17 1996-05-07 E. R. Squibb & Sons, Inc. Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
WO1994018989A1 (en) * 1993-02-22 1994-09-01 Cavalier Pharmaceuticals, Inc. Use of heparin to inhibit interleukin-8
ZA941290B (en) * 1993-02-26 1995-08-25 Res Dev Foundation Combination cisplatin/tamoxifen therapy for human cancers
GB9311948D0 (en) * 1993-06-10 1993-07-28 Zeneca Ltd Substituted nitrogen heterocycles

Also Published As

Publication number Publication date
US5656626A (en) 1997-08-12
NZ266855A (en) 1997-09-22
IL109968A (en) 1999-11-30
IL109968A0 (en) 1994-10-07
HU9501709D0 (en) 1996-03-28
WO1994029275A1 (en) 1994-12-22
ES2112546T3 (es) 1998-04-01
ATE163409T1 (de) 1998-03-15
US5502048A (en) 1996-03-26
TW282459B (de) 1996-08-01
GB9311948D0 (en) 1993-07-28
AU6854494A (en) 1995-01-03
GB9411242D0 (en) 1994-07-27
CA2161251A1 (en) 1994-12-22
EP0702673B1 (de) 1998-02-25
DK0702673T3 (da) 1998-11-23
JPH08511513A (ja) 1996-12-03
DE69408668T2 (de) 1998-07-09
EP0702673A1 (de) 1996-03-27
AU684789B2 (en) 1998-01-08

Similar Documents

Publication Publication Date Title
DE69408668D1 (de) Benz(b)azepin-2,5-dione verwendbar in der behandlung neurodegenerativer störungen
DE69929235D1 (de) Spiro-indole als y5-rezeptor antagonisten
JO2359B1 (en) Benzathene derivatives as agents for modulation of GABA A receptor
DE69330754D1 (de) 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ[b]AZEPINE ALS NMDA REZEPTOR ANTAGONISTEN
PL353854A1 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
FI943941A (fi) CCK-reseptoriantagonisteina käyttökelpoiset bentsodiatsepiinijohdannaiset
MY127686A (en) Monofluoroalkyl derivatives
WO2000042031A3 (en) Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
IS4722A (is) Notkun 1-(2-naft-2-ýletýl)-4(3-tríflúorómetýlfenýl)-1,2,3,6-tetrahýdrópýridíns til gerðar lyfja tilþess að meðhöndla hliðarstrengjahersli
AU3745795A (en) Use of CCK-B receptor antagonists for the treatment of sleepdisorders
ZA978792B (en) N-substituted azaheterocyclic compounds.
NZ329839A (en) Combination of a compound which inhibits acetylcholinesterase or exhibits muscarinergic action and a compound which increases the endogenous extracellular adenosine level for treating dementia
ATE221066T1 (de) Heterozyklische verbindungen
AU2002219192A1 (en) Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect
IL123536A0 (en) 5-HT3 Receptor antagonists for dyskinesia
ATE209036T1 (de) Verwendung von imidazo(a,5-a)quinolonen als neuroprotektive arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASTRAZENECA UK LTD., LONDON, GB

8339 Ceased/non-payment of the annual fee